Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NViroMune is a private U.S. nutraceutical and consumer health company marketing branded dietary supplements focused on immune support, post-viral symptom support, and bone health. Its lead commercial products include DEFENSE, positioned as an anti-viral replication and immune support supplement, and RESTORE, positioned for persistent post-COVID symptoms; the company also markets BONE-VIVA for bone health. NViroMune presents its products as proprietary, patent-pending combinations of GRAS-designated nutrients and plant bio-extracts developed with input from physicians and academic collaborators, particularly around Tel Aviv University-linked research. The business appears to operate as a supplement company rather than a traditional drug-development biotech, with products sold directly online and through retail marketplaces. Publicly available information does not indicate approved prescription therapeutics or a conventional clinical-stage biopharma pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NViroMune.